Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

[1] Abd El-Rehim DM(2004)Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma Br J Cancer 91 1532-1542

[2] Pinder SE(2004)Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol Biol Cell 15 5268-5282

[3] Paish CE(2007)A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395-402

[4] Bell JA(2005)Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer Clin Breast Cancer 6 247-252

[5] Rampaul RS(2000)PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases Hum Pathol 31 312-317

[6] Blamey RW(2011)Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers J Clin Oncol 29 166-173

[7] Robertson JF(2008)Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781-2790

[8] Nicholson RI(2005)Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation Exp Cell Res 304 604-619

[9] Ellis IO(2011)PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer Am J Pathol 177 1647-1656

[10] Austin CD(2009)MUC1 Breast Cancer Res Treat 118 113-124

[1] Abd El-Rehim DM(2004)Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma Br J Cancer 91 1532-1542

[2] Pinder SE(2004)Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol Biol Cell 15 5268-5282

[3] Paish CE(2007)A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395-402

[4] Bell JA(2005)Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer Clin Breast Cancer 6 247-252

[5] Rampaul RS(2000)PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases Hum Pathol 31 312-317

[6] Blamey RW(2011)Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers J Clin Oncol 29 166-173

[7] Robertson JF(2008)Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781-2790

[8] Nicholson RI(2005)Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation Exp Cell Res 304 604-619

[9] Ellis IO(2011)PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer Am J Pathol 177 1647-1656

[10] Austin CD(2009)MUC1 Breast Cancer Res Treat 118 113-124